Table 1.
Comparison of clinicopathological features of 148 lung neuroendocrine tumours across the four histotypes defined by the World Health Organization classification
| Clinicopathological features | TC (n = 53) | AC (n = 35) | LCNEC (n = 27) | SCLC (n = 33) | p‐Value * |
|---|---|---|---|---|---|
| Mean age (years) ± SD | 54.1 ± 15.3 | 61.2 ± 15.1 | 70.4 ± 7.2 | 66.9 ± 9.4 | < 0.0001† |
| Females/males (no.) | 33/20 | 20/15 | 5/22 | 10/23 | 0.0002 |
| Smokers/non‐smokers (no.) | 17/13 | 15/11 | 16/6 | 26/1 | 0.0013 |
| Missing value (no.) | 23 | 9 | 5 | 6 | |
| Median tumour size (cm) | 2.5 | 2.8 | 3.3 | 2.8 | 0.10‡ |
| 1st–3rd quartile | 1.7–3.2 | 1.6–4.4 | 2.3–3.8 | 2.4–3.5 | |
| Missing value (no.) | 0 | 0 | 1 | 14 | |
| Mitotic count (mean) | 0.6 | 3.5 | 36.0 | 36.7 | < 0.0001† |
| Range | 0–1 | 1–7 | 11–79 | 18–130 | |
| Ki67 index (mean) | 3.7 | 12.5 | 71.2 | 65.3 | < 0.0001† |
| Range | 1–15 | 2–45 | 20–95 | 40–95 | |
| pT (no.) | < 0.0001 | ||||
| T1 | 35 | 16 | 8 | 8 | |
| T2 | 15 | 14 | 11 | 10 | |
| T3 | 2 | 5 | 7 | 3 | |
| T4 | 1 | 0 | 1 | 12 | |
| pN (no.) | < 0.0001 | ||||
| N0 | 48 | 24 | 18 | 4 | |
| N1 | 4 | 8 | 3 | 9 | |
| N2 | 1 | 3 | 5 | 19 | |
| N3 | 0 | 0 | 1 | 1 | |
| pM (no.) | < 0.0001 | ||||
| M0 | 53 | 34 | 24 | 22 | |
| M1 | 0 | 1 | 3 | 11 | |
| Tumour stage (no.) | < 0.0001 | ||||
| I | 46 | 17 | 11 | 2 | |
| II | 4 | 15 | 8 | 4 | |
| III | 3 | 2 | 5 | 16 | |
| IV | 0 | 1 | 3 | 11 |
AC, atypical carcinoid; LCNEC, large‐cell neuroendocrine carcinoma; SCLC, small‐cell lung cancer; SD, standard deviation; TC, typical carcinoid.
*
Fisher's exact test was used for categorical variables. Fisher's test with Monte Carlo simulation was used for pT, pN, pM, and tumour stage. The Shapiro–Wilk test was used to test the Gaussian distribution of continuous variables.
†
The Kruskal–Wallis test was used for age.
‡
One‐way anova on log‐transformed data for tumour size.